IL269746A - Compositions and methods for targeting and killing alpha-V-3-positive cancer stem cells and treating drug-resistant cancer - Google Patents

Compositions and methods for targeting and killing alpha-V-3-positive cancer stem cells and treating drug-resistant cancer

Info

Publication number
IL269746A
IL269746A IL26974619A IL26974619A IL269746A IL 269746 A IL269746 A IL 269746A IL 26974619 A IL26974619 A IL 26974619A IL 26974619 A IL26974619 A IL 26974619A IL 269746 A IL269746 A IL 269746A
Authority
IL
Israel
Prior art keywords
cscs
killing
targeting
beta
alpha
Prior art date
Application number
IL26974619A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL269746A publication Critical patent/IL269746A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL26974619A 2017-03-31 2019-10-02 Compositions and methods for targeting and killing alpha-V-3-positive cancer stem cells and treating drug-resistant cancer IL269746A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479768P 2017-03-31 2017-03-31
PCT/US2018/025470 WO2018183894A1 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Publications (1)

Publication Number Publication Date
IL269746A true IL269746A (en) 2019-11-28

Family

ID=63676868

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26974619A IL269746A (en) 2017-03-31 2019-10-02 Compositions and methods for targeting and killing alpha-V-3-positive cancer stem cells and treating drug-resistant cancer

Country Status (12)

Country Link
US (2) US20200109205A1 (show.php)
EP (2) EP3600422B1 (show.php)
JP (2) JP2020512978A (show.php)
KR (1) KR102630070B1 (show.php)
CN (1) CN110662559A (show.php)
AU (1) AU2018243670B2 (show.php)
BR (1) BR112019020451A2 (show.php)
CA (1) CA3058458A1 (show.php)
EA (1) EA201992326A1 (show.php)
IL (1) IL269746A (show.php)
MX (1) MX2019011717A (show.php)
WO (1) WO2018183894A1 (show.php)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557246B (zh) 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
EP4110822A4 (en) * 2020-04-23 2024-04-10 Alpha Beta Holdings, LLC COMPOSITIONS AND METHODS FOR TREATING CANCER
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用
CN118284622A (zh) * 2021-09-30 2024-07-02 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
AU733303C (en) * 1996-05-31 2002-08-08 Scripps Research Institute, The Methods and compositions useful for inhibition of angiogenesis
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2294900A1 (en) 1997-07-02 1999-01-14 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
DE60028567T2 (de) 1999-04-23 2007-05-16 Mitsubishi Chemical Corp. Antikörper und polyalkylenglycol gebundenes liposom
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1698329A4 (en) 2003-12-24 2009-10-28 Ltt Bio Pharma Co Ltd PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
EP1722762A2 (en) 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
CA2614046C (en) * 2005-06-30 2018-05-15 Centocor, Inc. Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof
CN103989633A (zh) 2005-07-27 2014-08-20 普洛体维生物治疗公司 制造脂质体的系统和方法
US20080088046A1 (en) 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP2298308B1 (en) * 2005-11-14 2013-01-16 University Of Southern California Integrin-binding small molecules
US20080089928A1 (en) 2006-06-13 2008-04-17 Stavroula Sofou Liposome drug carriers with ph-sensitivity
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US20140154264A1 (en) * 2011-06-02 2014-06-05 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CA2925057A1 (en) * 2013-10-01 2015-04-09 Simon T. BARRY Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
CN113307873B (zh) * 2013-11-11 2025-02-18 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Also Published As

Publication number Publication date
WO2018183894A1 (en) 2018-10-04
EP4353318A3 (en) 2024-07-17
KR102630070B1 (ko) 2024-01-26
CN110662559A (zh) 2020-01-07
US20200109205A1 (en) 2020-04-09
EP3600422B1 (en) 2023-10-18
EA201992326A1 (ru) 2020-03-13
CA3058458A1 (en) 2018-10-04
EP4353318A2 (en) 2024-04-17
KR20190133205A (ko) 2019-12-02
AU2018243670A1 (en) 2019-10-31
AU2018243670B2 (en) 2025-05-01
MX2019011717A (es) 2019-12-16
BR112019020451A2 (pt) 2020-04-28
US20240067733A1 (en) 2024-02-29
JP2020512978A (ja) 2020-04-30
EP3600422A4 (en) 2021-01-13
JP2021095423A (ja) 2021-06-24
EP3600422A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
IL269746A (en) Compositions and methods for targeting and killing alpha-V-3-positive cancer stem cells and treating drug-resistant cancer
IL271946A (en) Combination for cancer treatment
IL259017A (en) Cancer cure is intended
EP3574018A4 (en) CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
IL287644A (en) Cytarabine conjugates for cancer treatment
IL271849A (en) Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy
HK1221424A1 (zh) 治疗癌症的药物组合
IL265697A (en) Prostate cancer treatment
IL273195A (en) Castration-resistant prostate cancer
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
ZA202002663B (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
IL292718A (en) Cancer treatments that target cancer stem cells
IL268416A (en) Pharmaceutical combinations for cancer treatment
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
EP3560494A4 (en) MEDICINAL PRODUCT TARGETING A CARCINOUS STEM CELL
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
IL289476A (en) Compositions and methods for targeting alpha-v-neta-3 positive cancer stem cells and killing and treating drug-resistant and metastatic cancers
PT3737397T (pt) Vacinas anticancro direcionadas contra prame e utilizações das mesmas
GB201716408D0 (en) Stem cell microparticles for cancer therapy
SG11202101425WA (en) Cancer stem cell marker and cancer stem cell targeting drug
EP3562509A4 (en) REDUCING CHEMOTHERAPY DAMAGE AND INCREASING CANCER KILL RATES FROM THE USE OF LOW-DOSE RADIATION CROSS-LINKING AGENTS
IL248328A0 (en) Bracelets for the administration of drugs for the treatment of resistant cancer and for the use of combined therapy
IL274748A (en) Improved cancer treatment
GB201704909D0 (en) Cancer therapy